Business Context and Reporting Period
This Form 8-K is a current report filed by Pliant Therapeutics, Inc. (PLRX) on October 20, 2025. The filing addresses a specific corporate governance event regarding the departure of a senior executive.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
On October 20, 2025, the Company accepted the resignation of Hans Hull as Chief Business Officer, effective immediately. The Company explicitly stated that the resignation was not due to any disagreement regarding the Company's operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future strategy, or discussion of risks and contingencies beyond the executive departure. No unusual items were reported.
Investor Verification Checklist
- Verify the effective date of Hans Hull's resignation (October 20, 2025).
- Confirm the stated reason for departure (no disagreement with operations or policies).
- Check for subsequent announcements regarding the appointment of a replacement Chief Business Officer.
- Review the Company's most recent 10-Q or 10-K for current financial status, as this 8-K contains no financial data.